产品
编 号：F198294
分子式：C18H18ClN5O
分子量：355.82
分子式：C18H18ClN5O
分子量：355.82
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 164658-13-3
产品详情
生物活性：
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor.
体内研究：
CGP-60474 (10?mg/kg; i.p.) inhibits the IL-6 level and increases the survival rate in the LPS endotoxemia model.Animal Model:C57Bl/6 mice (LPS endotoxemia model)
Dosage:10?mg/kg
Administration:I.p.
Result:Had a higher survival rate.
体外研究：
CGP60474 (Compound A) is a potent VEGFR-2 inhibitor, with an IC50 of 84 nM. CGP60474 is also a PKC inhibitor, with competitive kinetics relative to ATP.
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor.
体内研究：
CGP-60474 (10?mg/kg; i.p.) inhibits the IL-6 level and increases the survival rate in the LPS endotoxemia model.Animal Model:C57Bl/6 mice (LPS endotoxemia model)
Dosage:10?mg/kg
Administration:I.p.
Result:Had a higher survival rate.
体外研究：
CGP60474 (Compound A) is a potent VEGFR-2 inhibitor, with an IC50 of 84 nM. CGP60474 is also a PKC inhibitor, with competitive kinetics relative to ATP.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备